Clinical Trial Update: Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating toremifene citrate to reduce the risk of new bone fractures in men with prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Toremifene citrate (toremifene citrate)

Snippet

Sponsor: GTx | Conditions: Risk of Bone Fracture Occurrences | Phase 3 | Status: WITHDRAWN